To evaluate chemotherapy and decitabine treatment for acute myeloid leukemia
Recruiting
- Conditions
- CancerAcute myeloblastic leukaemia [AML]Acute myeloid leukemia (AML)
- Registration Number
- ISRCTN24452099
- Lead Sponsor
- Heilongjiang Institute for Hematology and Oncology Research (China)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
1. Any age AML patients (except APL) at different treatment stages, who are responsive or non-responsive to conventional treatments are all included in this trial
2. Patients agreed to receive the treatment
Exclusion Criteria
1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc.)
2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc.)
3. Illegal drug use or chronic alcoholism
4. Physical limitations, mental or intellectual disabilities
5. Any condition that may affect the development of this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient disease-free survival and overall survival
- Secondary Outcome Measures
Name Time Method 1. Patient drug concentrations<br>2. Patient AML burden during each treatment period<br>3. Drug side effects evaluation<br>4. Patient relapse-free survival<br>5. Patient overall survival<br><br>To monitor the primary and secondary clinical outcomes, patients' peripheral blood and bone marrow samples were tested at diagnosis, and at the end of each treatment cycle: blood cell count and staining, flow cytometry, RT-PCR and in-situ hybridization are used to test cell morphology, gene mutations, and cytogenetic changes.